Amylyx Pharmaceuticals (AMLX) EBITDA Margin (2021 - 2024)
Amylyx Pharmaceuticals (AMLX) recorded quarterly EBITDA Margin of 31673.38% in Q4 2024, down 74.15% quarter-over-quarter from 18187.74% in Q3 2024, and down 3167593.0% on a YoY basis from N/an in Q1 2024.
Amylyx Pharmaceuticals (AMLX) EBITDA Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals' EBITDA Margin history runs 4 years deep, the most recent figure standing at 31673.38% for Q4 2024.
- In Q4 2024, EBITDA Margin fell 3167593.0% year-over-year to 31673.38%; the TTM figure through Sep 2025 stood at 14425.41% (down 1426152.0% YoY), while the FY2024 annual figure was 72.62%, down 8281.0% from the prior year.
- EBITDA Margin was 31673.38% for Q4 2024 at Amylyx Pharmaceuticals, down from 18187.74% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 18.63% in Q2 2023 to a low of 31673.38% in Q4 2024.
- Historically, EBITDA Margin has averaged 6878.42% across 4 years, with a median of 205.66% in 2022.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin surged 1001476 bps in 2023, then sank 3167593 bps in 2024.
- A 4-year view of EBITDA Margin shows it stood at 8041.4% in 2021, then soared by 97 bps to 205.66% in 2022, then jumped by 101 bps to 2.55% in 2023, then sank by 1244173 bps to 31673.38% in 2024.
- The last three EBITDA Margin figures came in at 31673.38% (Q4 2024), 18187.74% (Q3 2024), and 7457.09% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Amylyx Pharmaceuticals | 1.51 Bn | 1.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -31,673.38% |
| Sep 30, 2024 | -18,187.74% |
| Jun 30, 2024 | -7,457.09% |
| Mar 31, 2024 | -137.78% |
| Dec 31, 2023 | 2.55% |
| Sep 30, 2023 | 18.23% |
| Jun 30, 2023 | 18.63% |
| Mar 31, 2023 | -2.43% |
| Dec 31, 2022 | -205.66% |
| Sep 30, 2022 | -9,996.53% |
| Sep 30, 2021 | -8,041.40% |